[{"orgOrder":0,"company":"Inipharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Inipharm"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Aligos Therapeutics"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Announces Collaboration with Alnylam to Explore Targeted Therapy to Restore Liver Function","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$466.0 million","upfrontCash":"$60.0 million","newsHeadline":"Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Verve Therapeutics"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos\u2019 Oligonucleotide Platform for the Treatment of Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Aligos Therapeutics"},{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Tome Biosciences"},{"orgOrder":0,"company":"Evotec","sponsor":"Variant Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,035.0 million","upfrontCash":"$35.0 million","newsHeadline":"Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Ochre Bio"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$100.0 million","newsHeadline":"Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mammoth Biosciences"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the collaboration, Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies are set to advance in vivo programs in multiple tissue and cell types.
The partnership is focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
The strategic partnership leverages Variant Bio's cutting-edge genomic discovery capabilities and VB-Inference platform to identify a best-in-class small molecule treatment for diseases caused by fibrosis.
The Company intends to use the net proceeds to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.
Under the terms of the agreement, Aligos and Amoytop will use Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
Under the terms of the collaboration, Verve will advance the discovery, research and certain preclinical development of a novel in vivo gene editing program for the target of interest, with all program costs funded by Vertex.
Under the original agreement, Merck and Aligos committed to applying Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a certain undisclosed non-alcoholic steatohepatitis (NASH) target.
Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease.
Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of gene editing technology.